Community Trust & Investment Co. Has $14 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Community Trust & Investment Co. increased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 79,434 shares of the medical research company's stock after buying an additional 2,194 shares during the quarter. Community Trust & Investment Co.'s holdings in IQVIA were worth $14,004,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. American National Bank & Trust acquired a new position in shares of IQVIA in the first quarter valued at approximately $26,000. ST Germain D J Co. Inc. increased its position in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in IQVIA during the 4th quarter valued at approximately $39,000. Lee Danner & Bass Inc. acquired a new stake in IQVIA during the 4th quarter valued at approximately $44,000. Finally, Zions Bancorporation N.A. increased its position in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on IQV. Citigroup reissued a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. UBS Group decreased their target price on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Barclays cut their price target on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. HSBC cut IQVIA from a "buy" rating to a "hold" rating and cut their price target for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Finally, Truist Financial cut their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Trading Down 1.6%

NYSE IQV opened at $156.65 on Monday. The stock has a market capitalization of $27.10 billion, a price-to-earnings ratio of 20.89, a PEG ratio of 1.99 and a beta of 1.28. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business's fifty day moving average is $147.59 and its 200-day moving average is $177.34.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the business posted $2.54 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.